RIG012 is a potent antagonist of Retinoic Acid Inducible Gene 1 (RIG-I), an innate immune receptor, with an IC50 of 0.71 μM in the NADH-coupled ATPase assay. It effectively blocks RIG-I-initiated signaling and inflammatory responses induced by SARS-CoV-2 RNA.